Aktis Oncology Q2 net loss $24.1M; cash $517.3M funds operations into 2029

Aktis Oncology, Inc.

Net loss $24.1M for Q2 2026 vs $18.1M prior-year; interest income net of $4.8M.
Cash, equivalents, marketable securities $517.3M at June 30, 2026 vs $226.8M Dec 31, 2025.
Collaboration revenue $3.4M (Q2 2026) vs $1.6M prior-year, from Eli Lilly partnership.
R&D expenses $25.3M, up from $18.6M; G&A $7.0M vs $3.9M year-over-year.
Phase 1b trials: AKY-1189 (NECTINIUM-2) enrolling; AKY-2519 BActinium-2 to start H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.